top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

B. Lynne Parshall, Esq. net worth and biography

B. Parshall, Esq. Biography and Net Worth

Director of Ionis Pharmaceuticals

Ms. Parshall has served on the Ionis board since September 2000 and as a senior strategic advisor to Ionis since January 2018. Previously she served as our chief operating officer from December 2007 through December 2017 and as chief financial officer from June 1994 through December 2012. She also served as Ionis’ corporate secretary through 2014, and has served with the company in various executive roles since November 1991. Prior to joining Ionis, Ms. Parshall practiced law at Cooley LLP, outside counsel to Ionis, where she was a partner from 1986 to 1991. Ms. Parshall is a member of the American and California bar associations. Ms. Parshall serves on the board of directors of Cytokinetcs Inc. and Akcea Therapeutics, Inc.

What is B. Lynne Parshall, Esq.'s net worth?: The estimated net worth of B. Lynne Parshall, Esq. is at least $3.51 million as of December 26th, 2023. Ms. Parshall, Esq. owns 82,588 shares of Ionis Pharmaceuticals stock worth more than $3,505,861 as of April 25th. This net worth approximation does not reflect any other investments that Ms. Parshall, Esq. may own. Learn More about B. Lynne Parshall, Esq.'s net worth.
How do I contact B. Lynne Parshall, Esq.?: The corporate mailing address for Ms. Parshall, Esq. and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on B. Lynne Parshall, Esq.'s contact information.
Has B. Lynne Parshall, Esq. been buying or selling shares of Ionis Pharmaceuticals?: B. Lynne Parshall, Esq. has not been actively trading shares of Ionis Pharmaceuticals over the course of the past ninety days. Most recently, B Lynne Parshall sold 42,525 shares of the business's stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $50.19, for a transaction totalling $2,134,329.75. Following the completion of the sale, the director now directly owns 82,588 shares of the company's stock, valued at $4,145,091.72. Learn More on B. Lynne Parshall, Esq.'s trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, insiders at the sold shares 28 times. They sold a total of 291,805 shares worth more than $14,352,782.01. The most recent insider tranaction occured on April, 16th when EVP Joseph Baroldi sold 4,006 shares worth more than $166,649.60. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 4/16/2024.

B. Lynne Parshall, Esq. Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/28/2023	Sell	42,525	$50.19	$2,134,329.75	82,588
12/26/2023	Sell	25,113	$51.46	$1,292,314.98	82,588
9/26/2023	Sell	10,000	$45.13	$451,300.00	82,588
12/23/2020	Sell	10,000	$60.00	$600,000.00	57,464
11/25/2020	Sell	3,590	$50.05	$179,679.50	71,054
11/23/2020	Sell	3,200	$50.12	$160,384.00	70,664
4/29/2019	Sell	50,000	$75.01	$3,750,500.00	102,677
3/12/2019	Sell	8,334	$75.00	$625,050.00	61,011
2/27/2019	Sell	8,333	$70.00	$583,310.00	61,010
1/16/2018	Sell	5,986	$51.76	$309,835.36	44,166
10/18/2017	Sell	16,118	$65.00	$1,047,670.00	33,526
3/1/2017	Sell	4,625	$49.26	$227,827.50	30,276
1/17/2017	Sell	7,246	$46.29	$335,417.34	19,459
12/15/2016	Sell	4,000	$50.00	$200,000.00	16,693
12/1/2016	Sell	12,500	$42.23	$527,875.00	23,693
9/1/2016	Sell	12,500	$29.88	$373,500.00	25,558
1/19/2016	Sell	5,192	$41.46	$215,260.32	16,290
1/4/2016	Sell	809	$61.05	$49,389.45	8,215
10/2/2015	Sell	12,436	$40.75	$506,767.00	8,143
7/6/2015	Sell	6,218	$57.01	$354,488.18
7/1/2015	Sell	6,218	$57.56	$357,908.08
4/7/2015	Sell	5,565	$63.07	$350,984.55
1/16/2015	Sell	4,093	$67.96	$278,160.28
1/2/2015	Sell	11,200	$62.12	$695,744.00
10/30/2014	Sell	11,071	$45.12	$499,523.52
1/30/2014	Sell	89,510	$49.49	$4,429,849.90	4,022
1/16/2014	Sell	1,641	$47.08	$77,258.28	4,022
12/26/2013	Sell	37,811	$40.91	$1,546,848.01	956
12/24/2013	Sell	70,000	$41.49	$2,904,300.00	956
9/20/2013	Sell	90,000	$35.43	$3,188,700.00	956
9/11/2013	Sell	63,505	$31.04	$1,971,195.20

B. Lynne Parshall, Esq. Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $42.45

$41.59

$42.72

50 Day Range

MA: $43.53

$40.68

$49.07

2 Week Range

Now: $42.45

$34.32

$54.44

Volume

731,441 shs

Average Volume

1,136,506 shs

Market Capitalization

$6.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39